CALR and cancer: Just recently, using in silico prediction analyses, Schischlik and colleagues showed that both the CALR and MPL mutations generate neo-antigens that may bind to common HLA-I molecules, and additionally showed that the SF3B1 mutations that are identified occasionally in MPN may be a rich source of neo-antigens that may be targeted by cancer immune therapy [109].